OCEANS , a randomized , placebo-controlled , phase III trial , found that adding bevacizumab to gemcitabine-carboplatin ( GC ) significantly improved investigator-determined progression-free survival ( PFS ) and objective response rate ( ORR ) in platinum-sensitive , recurrent ovarian cancer .